Fiche centre
Clinical Research Institute
Minneapolis — United States
Essais liés11clinical trials
VilleMinneapolislocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06995729
Essais cliniques associés
11| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| K-645 100 mg | Migraine | Phase 2 | NCT07116499 | A Study of K-645 in the Treatment of Multiple Migraine Attacks | TERMINATED |
| Zavegepant | Migraine | Phase 1 | NCT06995729 | A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | RECRUITING |
| Elismetrep (K-304) 2 mg | Migraine | Phase 2 | NCT06848075 | A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT03235479 | Safety and Efficacy Study in Adult Subjects With Acute Migraines | COMPLETED |
| AMG334 | Migraine | Phase 4 | NCT03927144 | Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT05156398 | Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects | RECRUITING |
| Elismetrep | Migraine | Phase 3 | NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
| Elismetrep | Migraine | Phase 3 | NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT02614261 | REGAIN — Evaluation of Galcanezumab in the Prevention of Chronic Migraine | COMPLETED |